The anaphase-promoting complex (APC/C), a ubiquitin ligase, is the target of the spindle-assembly checkpoint (SAC), and it ubiquitylates protein substrates whose degradation regulates progress through mitosis [1] [2] [3] . The identity of the ubiquitinconjugating (E2) enzymes that work with the APC/C is unclear. In an RNA interference (RNAi) screen for factors that modify release from drug-induced SAC activation, we identified the E2 enzyme UBE2S as an APC/C auxiliary factor that promotes mitotic exit. UBE2S is dispensable in a normal mitosis, but its depletion prolongs drug-induced mitotic arrest and suppresses mitotic slippage. In vitro, UBE2S elongates ubiquitin chains initiated by the E2 enzymes UBCH10 and UBCH5, enhancing the degradation of APC/C substrates by the proteasome. Indeed, following release from SAC-induced mitotic arrest, UBE2S-depleted cells neither degrade crucial APC/C substrates, nor silence this checkpoint, whereas bypassing the SAC through BUBR1 depletion or Aurora-B inhibition negates the requirement for UBE2S. Thus, UBE2S functions with the APC/C in a two-step mechanism to control substrate ubiquitylation that is essential for mitotic exit after prolonged SAC activation, providing a new model for APC/C function in human cells.
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Inactivation of the SAC when all chromosomes have a bipolar attachment to spindle microtubules 1 allows the APC/C to mark cell-cycle regulated proteins such as cyclin B1 and securin for degradation by the 26S proteasome, thereby initiating anaphase 4, 5 . Which E2 enzyme(s) work with the APC/C in vivo is unclear: in vitro, the APC/C can work with the Ubc4/5 and E-2C families (in particular, human UBCH5 and UBCH10, respectively) 6 . Evidence from simple model organisms indicates that E2-C family members are most likely to be biologically relevant [7] [8] [9] [10] [11] [12] , but short interfering (siRNA) studies in human cells disagree over whether UBCH10 is essential for mitosis 13, 14 . Moreover, APC/C activity in model organisms may not depend solely on a single E2 partner. For instance, budding yeast Ubc1 is a supplementary E2 enzyme that elongates ubiquitin chains initiated by a proximally-acting E2 enzyme 11 . The identity and activity of E2 partner enzymes could be an important determinant for the efficiency of APC/C-targeted degradation, and thus exit from mitosis, because ubiquitin chain length modulates recognition by the proteasome 15 . The mechanism and efficiency of APC/C-targeted degradation probably affects the cellular outcome of mitotic arrest induced by anti-cancer drugs, such as taxanes, after which cells undergo mitotic slippage, and may either abnormally exit mitosis to form aneuploid progeny, or die [16] [17] [18] . We searched for genes that modify release from drug-induced mitotic arrest (Fig. 1a) in human Cal51 cells. We used siRNA to deplete 520 components of the ubiquitin-proteasome system (Supplementary Information, Table 1 ), and determined the percentage of mitotic cells (mitotic index; MI) by high-content microscopy (Fig. 1b) . The MI of cells 20 h after exposure to monastrol (Mona; MI Mona ), was compared with the MI of DMSO-treated control cells (MI DMSO ). The difference, ∆MI = MI Mona -MI DMSO , was calculated for each siRNA (Fig. 1c) . The screen results are summarised in Supplementary Information, Table 2 . Putative hits were defined as samples showing a ∆MI standard score > 2 and a significant difference from a non-targeting siRNA (P < 0.01, Student's t-test). UBE2S (also known as E2-EPF) and PRPF8 were the only two candidates fulfilling these criteria. PRPF8 was not studied further because at later time points its depletion induced mitotic arrest even without monastrol treatment (data not shown). The phenotypic effects of UBE2S depletion were confirmed using four different siRNA oligonucleotides targeting discrete regions of its transcript (Fig. 1d) , with the largest increase observed for oligonucleotide D2 (Fig. 1e) .
We compared the ∆MI between UBE2S-depleted cells that were continually exposed to monastrol and UBE2S-depleted cells at 20 h after release from exposure ( Fig. 2a, b) . Only 35-70% of UBE2S-depleted cells exited mitosis during this period compared with 90% of control cells. UBE2S depletion also suppressed mitotic slippage in cells continually exposed to monastrol (Fig. 2b) . Only 25-35% of UBE2S-depleted cells underwent mitotic slippage during continual drug exposure, versus ~60% of control cells.
UBE2S depletion significantly impaired the ability of cells to resume mitotic progression after exposure to S-trityl-l-cysteine and Dimethylenastron (which, like monastrol, inhibit the mitotic kinesin Eg5; refs [19] [20] [21] [22] , or mitotic inhibitors with different modes of action such as taxol and nocadazole, which stabilize or suppress microtubule assembly, respectively (Fig. 2c) . UBE2S depletion had the largest effect after taxol exposure, and the smallest after monastrol, consistent with the magnitude of the initial mitotic arrest induced by these compounds (Fig. 5c ). These effects were manifest in several cell types, including the cervical cancer cell line, HeLa, as well as immortalized retinal pigmented epithelial (RPE) cells (Fig. 2d, e) .
We further examined the kinetics of checkpoint arrest and mitotic slippage after UBE2S depletion by analysing monastrol-arrested cells released into drug-free media. Approximately 35% of control-treated cells exited mitosis in the first 3 h, and most (85%) by 12 h (Fig. 3a) . UBE2S depletion significantly delayed mitotic exit: even by 12 h, only about 30% of cells had exited. A similar delay occurred in individual cells examined by time-lapse imaging (Fig. 3b) . The average time to exit mitosis after release from drug-induced arrest was 255 ± 169 min (n = 49 cells) in control cells versus 668 ± 412 min (n = 48) after UBE2S depletion. Similar effects occurred after release from a short (6 h) arrest in synchronised cells; thus, the duration of arrest did not alter the requirement for UBE2S ( Supplementary Information, Fig. S1a ).
UBE2S also influenced mitotic slippage during sustained inhibitor treatment (Fig. 3c) . In contrast to control cells, UBE2S depletion markedly decreased mitotic slippage, with an increased MI 24 h after taxol addition, and a delay in mitotic slippage by most cells at 72 h after taxol addition. Moreover, time-lapse imaging showed that there was a significant increase in the duration of mitosis. About 90% (n = 87) of control cells underwent mitotic slippage within 1,000 min (~17 h), whereas during the same period only 47% (n = 109) of UBE2S-depleted cells did (Fig. 3d) .
A small increase in the MI occurred after UBE2S depletion even without any inhibitor treatment (Fig. 2b, oligonucleotide D2 ), prompting us to examine closely the role of UBE2S in normal mitosis, using time-lapse microscopy with cell lines expressing histone H2B-GFP. UBE2S depletion only modestly increased the time from nuclear envelope breakdown (NEBD) to anaphase in HeLa or Cal51 cells (Fig. 3e) , and did not detectably affect the degradation of cyclin B1-GFP ( Supplementary  Information, Fig. S1b) . In Cal51 cells, the average duration of mitosis significantly increased from 28.7 ± 14 min (n = 110 cells) in control cells, to 34.1 ± 14.4 min (n = 113) after UBE2S depletion (P < 0.01). In HeLa cells (Fig. 3e) , the average duration increased from 43.4 ± 17.2 min (n = 174 cells) in control cells to 55 ± 23 min after UBE2S depletion (n = 124; P < 0.001). In contrast, however, micro-injection of an untagged, catalytically inactive form of UBE2S into HeLa cells did not lengthen mitosis (46.6 ± 9.6 min; n = 19) compared with injection with wild-type UBE2S (42 ± 15 min; n = 24 cells; P > 0.1) or even uninjected cells (53.5 ±27.9 min; n = 89). Thus, our findings indicate that UBE2S is largely dispensable in unperturbed mitosis, but may have a modest, non-essential function. Alternatively, although UBE2S depletion using RNAi eliminated any protein detectable by western blotting, very small amounts may nevertheless have persisted, satisfying any requirement of normal mitosis. We determined the effect of UBE2S on the ubiquitylation of the anaphase inhibitors cyclin B1 and securin using reconstituted in vitro APC/C activity assays with purified protein components. In these assays, the APC/C ubiquitylated an amino-terminal fragment of cyclin B1 (aminoacids 1-86) when incubated with the E2 enzymes UBCH10 or UBCH5 (Fig. 4a) . In contrast, incubation of UBE2S alone with the APC/C did not catalyse ubiquitylation of cyclin B1 (Fig. 4a) , cyclin A ( Supplementary  Information, Fig. S2a ) or securin (data not shown). Notably, however, when UBE2S was added to the assays together with UBCH10 or UBCH5, the number of conjugated ubiquitin molecules per molecule of cyclin B1 was significantly increased (Fig. 4a) . As UBE2S did not catalyse substrate ubiquitylation on its own, this result indicated that UBE2S either enabled UBCH10 and UBCH5 to ubiquitylate additional lysines on cyclin B1, or that it elongated ubiquitin chains on pre-ubiquitylated lysines. To distinguish between these possibilities, we used methylated ubiquitin, which prevents the elongation but not initiation of ubiquitin chains (Fig. 4b) . UBE2S did not affect UBCH10 or UBCH5 ubiquitylation of cyclin B1 when using methylated ubiquitin, confirming that it can elongate ubiquitin chains on pre-ubiquitylated lysines, but does not initiate conjugation.
In budding yeast, the E2 enzyme Ubc1 extends ubiquitin chains pre-attached by the APC/C 11 . Therefore, we measured whether UBE2S could extend ubiquitin chains on a pre-ubiquitylated cyclin B1 substrate. Unexpectedly, we could not detect this activity with UBE2S alone, whereas the human homologue of yeast Ubc1 (E2-25K) and UBCH10 extended ubiquitin chains under the same conditions ( Supplementary Information,  Fig. S2b ). This result may indicate that UBE2S elongates ubiquitin chains by a different mechanism from enzymes such as E2-25K.
When we quantified the proportion of cyclin B1 conjugated with 1-4, 5-9 or > 9 ubiquitin molecules (Fig. 4c) , we found both UBCH10 and UBCH5 primarily conjugated 1-4 ubiquitin molecules to cyclin B1, but the addition of UBE2S significantly increased the proportion of cyclin B1 with > 9 ubiquitin molecules (Fig. 4c) . Representative activity assays used for the quantification are provided in Supplementary Information, Fig. S3 . A catalytically inactive version (C95S) of UBE2S was unable to promote longer chains, and combining UBCH5 and UBCH10 did not drastically change the chain length compared with UBCH5 alone (Fig. 4a  and 4c ). Similarly, combining UBCH10, UBCH5 and UBE2S together in a single ubiquitylation reaction did not increase polyubiquitination compared with reactions using UBE2S and UBCH10 or UBE2S and UBCH5 ( Supplementary Information, Fig. S4 ).
The addition of UBE2S to UBCH10 reactions reduced total ubiquitylation at earlier time points and this was dependent on UBE2S catalytic activity (Fig. 4c , compare ubiquitylation at 10 min from UBCH10, UBCH10 and UBE2S, and UBCH10 and UBE2S C95S). Possibly UBE2S and UBCH10 compete for binding to the APC/C; alternatively, substrates could dwell longer on a ternary APC/C-UBCH10-UBE2S complex, consistent with the requirement for pre-ubiquitylation by another E2 enzyme before UBE2S activity.
Our cellular studies indicated that the action of UBE2S might become more important for efficient substrate degradation when APC/C activity is compromised by prolonged SAC-induced arrest. To test this, drugarrested cells were collected by mitotic shake-off, and samples collected 3 and 9 h post-release for western blotting of APC/C substrates. In control cells, cyclin B1 and securin protein levels were high during mitotic arrest and mostly degraded by 3 h post-release (Fig. 5a ). In contrast, UBE2S depletion suppressed degradation of cyclin B1 and securin even at 9 h post-release. Additionally, the early mitotic APC/C substrates cyclin A and Nek2A 23, 24 , which are degraded during pro-metaphase when the SAC is active, accumulated in cells depleted of UBE2S (Fig. 5a) .
To quantify the effect of UBE2S on substrate degradation, we measured levels of GFP-tagged cyclin B1 during mitotic slippage (Fig. 5b) . As expected 18, 25 , we observed a slow decline in cyclin B1 levels during arrest, and a rapid decline around 10 min before exit from mitosis. As UBE2S-depleted cells showed a prolonged mitotic arrest, (Fig. 3c, d ), we measured the levels of cyclin B1 specifically during the slow degradation stage (Fig. 5b) . In UBE2S-depleted cells, the rate of cyclin B1 degradation decreased (from a slope of -1.4 × 10 to -0.65 × 10 -3 fluorescence units min -1 ) and the duration of mitotic slippage was significantly extended, compared with control cells. In contrast, UBE2S depletion had little effect on cyclin B1 degradation during normal unperturbed mitosis ( Supplementary Information,  Fig. S1b ), suggesting that UBE2S only becomes rate limiting after drug-induced SAC activation. Indeed, we found that mitotic arrest was evident in both control and UBE2S-depleted cells treated for 20 h (t = 20 arrest) with 12.5 μM of monastrol, but not with lower doses (Fig. 5c) . Correspondingly, UBE2S became necessary for mitotic exit after release from mitotic arrest (t = 40 release) and for slippage (t = 40 constant) only when when cells were treated with ~12.5 μM of monastrol. Similar results were obtained when cells were treated with a range of taxol concentrations (data not shown).
Interestingly, BUBR1 protein levels were increased in arrested cells depleted of UBE2S, and BUBR1 was hyper-phosphorylated, indicating that the SAC was active (Figs 5a, d ). BUBR1 forms an inhibitory complex with the APC/C co-activator CDC20 (refs 1, 3) , whose presence is a measure of SAC activity. In control cells, BUBR1 was complexed with CDC20 at the time of arrest (t = 0), and the CDC20-BUBR1 interaction was lost 9 h after release, during mitotic exit (Fig. 5d) . Following UBE2S depletion, however, BUBR1-CDC20 complex formation was increased both at the time of arrest, and 9 h after release, despite lower levels of CDC20 and BUBR1, indicating that the SAC remained active at least in a proportion of UBE2S-depleted cells.
A BUBR1 mutant resistant to APC/C-mediated degradation delays anaphase entry 26 . However, we found that both endogenous BUBR1, which co-purifies with the APC/C from SAC-arrested HeLa cells 27 , and recombinant BUBR1 are poor APC/C substrates in vitro ( Supplementary  Information, Fig. S5) . Therefore, although UBE2S may contribute to SAC inactivation by enhancing APC/C-mediated ubiquitylation of BUBR1, under our in vitro conditions BUBR1 is not a preferred substrate, and so other substrates may be involved in vivo.
If UBE2S helps to inactivate the SAC, then forced SAC inactivation should bypass the requirement for UBE2S in exit from mitosis. Indeed, co-depleting UBE2S with BUBR1 prevented mitotic arrest after treatment with monastrol or taxol (Fig. 5e) . Strikingly, the Aurora kinase inhibitor ZM 447439 (ref. 28) , which acutely inactivates the SAC in arrested cells (Fig. 5f, g ), triggered mitotic exit within 3 h in both control In vitro ubiquitylation reactions were performed as in a, but with shorter reaction times to prevent limited availability of unmodified substrate ( Supplementary Information, Fig. S3 ). Cyclin B1-ubiquitin conjugates with 1-4, 5-9 or > 9 ubiquitin molecules ( Supplementary Information,  Fig. S3 ) from three independent experiments were quantified. Data were normalized to the total amount of ubiquitylated cyclin B1 and plotted as stacked area charts. Error bars show mean ± s.e.m. and UBE2S-depleted cells (Fig. 5f ), whereas cells depleted of the APC/C co-activator CDC20 failed to exit mitosis even after 6 h. Moreover, cyclin B1 was degraded after ZM 447439 exposure in control and UBE2S-depleted cells (Fig. 5g) , consistent with its efficient APC/C-mediated degradation even after UBE2S depletion. Thus, collectively, our data indicate that UBE2S is necessary and rate limiting for SAC inactivation after drug-induced mitotic arrest.
In contrast, UBE2S depletion has little effect on normal mitotic progression (Fig. 3e) , and is largely dispensable for cyclin B1 degradation in this context ( Supplementary Information, Fig. S1b) . The difference in UBE2S functions can be explained as follows. The activity of the APC/C in ubiquitylating and promoting the proteasomal degradation of its substrates is normally opposed by the activity of antagonistic de-ubiquitylating enzymes [29] [30] [31] . By enhancing the formation of elongated ubiquitin chains, UBE2S should shift the equilibrium between these opposing activities, favouring substrate degradation by facilitating proteasomal recognition 15 . Although UBE2S may also act during unperturbed mitosis, its role becomes rate limiting during release from drug-induced SAC activation. This role is apparently both general and essential, manifesting in several cell types exposed to different antimitotic drugs. In this context, it seems that UBE2S is important for silencing the SAC, as forced SAC inactivation suffices to bypass UBE2S depletion and allows mitotic progression. Thus, our findings identify UBE2S as a regulator of mitosis, and suggest a new, two-step model for human APC/C function in which the E2 activity of UBE2S elongates ubiquitin chains that are initiated by a proximally-acting E2 enzyme, to promote APC/C-targeted substrate degradation. Table S1 ). Triplicate reverse transfections were performed in 96-well plates using Dharmafect I with 20,000 Cal51 cells and on-target (25 nM) plus siRNA pools containing four siRNAs targeting an individual gene (Dharmacon). 24 h following transfection monastrol (100 μM) or solvent control (DMSO) was added to triplicate plates for 20 h. During this period, cells arrested in mitosis and some cells began to undergo mitotic slippage. Media was then aspirated from wells, and replaced with fresh media before leaving for an additional 20 h. The control samples were collected 20 h following DMSO addition. Cells were fixed in 70% ethanol and stored at 4 °C. For antibody staining, cells were incubated in blocking solution (TBS, 0.1% Triton X-100 and 2% BSA) for 20 min, and then stained in blocking solution with the mitotic marker mouse anti-phospho S10 histone H3 (pSer10-H3; 1:1,000 dilution; Abcam) for 1 h at room temperature. A secondary antibody was conjugated with Alexa-633 dye (Invitrogen) and incubated for 1 h at room temperature in blocking buffer. After antibody staining, DNA was stained with Hoechst 33452 (4 μg/ ml -1
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; Sigma) in PBS for 30 min. Plates were sealed and stored in PBS at 4 °C in the dark before analysis.
Fluorescence images of stained cells were collected using a Cellomics Arrayscan high content fluorescence microscope (Thermo Scientific) and analysed using the Cellomics Morphology Explorer Bioapplication. DNA staining was used for object selection and data was collected for > 5000 objects (cells) in each well (or 40 images) to generate a histogram of raw average pSer10-H3 staining intensities. As cell density and inter-plate variability can shift the typical bimodal frequency of the histogram, an automatic and adaptive Two-Gaussian curvature-fitting program was developed in Matlab. Cells negative for pSer10-H3 staining were fitted with the first Gaussian curve, and cells positive for pSer10-H3 staining were fitted with the second Gaussian curve. This allowed corresponding gate thresholds for positive populations to be adaptively measured according to the Gaussian curvature parameters and reported as a percentage of the cells in each well.
Statistical analysis of screen data. Statistical analysis was performed using Microsoft Excel. Plate mitotic index values were normalized to the mean of plate medians for each of the DMSO-and monastrol-treated data sets. The data was manually curated to remove outliers for each set of three replicates. To calculate an average ΔMI for each gene, difference values were calculated by subtracting MI MONA -MI DMSO for each of the three replicates for each gene. A standard score using the average ΔMI was then calculated for each siRNA. Additionally, the ΔMI was used to perform a two-tailed non-parametric Student's t-test comparing to a non-targeting siRNA (Qiagen). Genes with a standard score > 2 and P < 0.01 were scored as putative hits for further analysis. As a control for sensitivity of the assay, an siRNA targeting the mitotic kinase Plk1 was used to induce a mitotic arrest and to calculate a Z-prime score. All plates used in the screen had a Z-prime score > 0.5 for Plk1 compared with control siRNA.
Cell culture and molecular cloning. Cells were grown at 37 °C with 5% CO 2 . Cal51 and HeLa cells were cultured in DMEM supplemented with 10% FCS and penicillin/streptavidin. RPE cells were cultured in F12:DMEM (1:1) media supplemented with 10% FCS, sodium bicarbonate, Glutamate and penicillin/streptavidin. All transfections were performed as described in the screen, except they were performed manually in 96-well or 6-well plates. The sequences of individual siRNA oligos targeting UBE2S were: D2 (5´-ACAAGGAGGUGACGACACU-3´); D4 (5´-CAUGCUGGCGAGCGCGAUA-3´); Q2 (5´-CCGCCU GCUCU-UGGAGAACUA-3´); and Q3 (5´-CCCGAU GGCAUCAAGGUCUUU-3´). siRNA targeting CDC20 was a siGENOME smartpool from Dharmacon. Cells were treated with monastrol (100 μM; Sigma), taxol (50 nM; Sigma), Dimethylenastron (2.5 μM) or S-trityl-l-cysteine (5 μM) for 20 h unless otherwise indicated. Cells were synchronised during G1/S phase of the cell cycle by performing a single thymidine block. Full-length cDNA for human UBE2S was obtained from the Mammalian Gene Collection I.M.A.G.E. consortium (Geneservice). A catalytically inactive version of UBE2S was generated by PCR mutagenesis by introducing a Ser for Cys substitution at amino acid position 95. Plasmids were verified by restriction enzyme mapping and sequencing.
Western blotting, immunoprecipitations and antibodies. Western blotting was performed using standard techniques. Primary antibodies were diluted as indicated and incubated with membranes for 2 h at room temperature: rabbit anti-UBE2S (1:500 dilution; Abnova), mouse anti-Cyclin B1 (1:1,000; Santa Cruz), anti-Securin (1:200; Santa Cruz), anti-Cyclin A (1:500; Santa Cruz), rabbit anti-Nek2A (1:200; BD Bioscience), mouse anti-BUBR1 (1:1,000; a gift from F. McKeon, Harvard Medical School, USA), mouse anti-βactin (1:2,000; Sigma), rabbit anti-CDC20 (1:200; Abcam). HRP-conjugated secondary antibodies were used at a 1:10,000 dilution and incubated with membranes for 1 h at room temperature before exposure using ECL. Whole cell extracts for western blotting were prepared with ice-cold RIPA buffer (50 mM Tris at pH 8.0, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP40, 0.1% 2-mercapatoethanol, protease inhibitor cocktail -Roche and phosphatase inhibitor cocktail I and II -Sigma). For co-immunoprecipiatation studies, whole cells extracts were prepared with ice-cold NP40 extraction buffer (100 mM Tris at pH 7.4, 100 mM NaCl, 0.1% NP40, 0.1% 2-mercapatoethanol, 5 mM EDTA, 10 mM MgCl 2 , protease inhibitor cocktail -Roche and phosphatase inhibitor cocktail I and II -Sigma). Extracts were centrifuged at 16,000g for 10 min and the soluble fraction collected. CDC20 co-immunoprecipitations were performed using ~1 μg antibody (sc5296, Santa Cruz) coupled to protein G sepharose.
Analysis by flow cytometry. Measurement of DNA content and antibody staining of the mitosis specific marker MPM2 were used to determine the population of mitotic cells. Briefly, ethanol-fixed cells were rinsed with PBS and incubated with a mouse anti-MPM2 antibody (1:200 dilution; Upstate) in PBS containing 1% fetal bovine serum (PBS/F) for 1 h at 37 °C. Cells were washed twice with PBS and incubated with Alexa-488 conjugated goat anti-mouse antibody (1:500; Invitrogen) in PBS/F for 1 h at room temperature. Cells were rinsed twice with PBS followed by staining with Propidium Iodide (Sigma) and analysed using standard methods. Mitotic cells had 4N DNA content and were positive for MPM2 staining.
Microinjection and time-lapse imaging. For microinjection and microscopy, cells were grown on a Bioptechs ΔT heated stage attached to a Leica DMIRBE microscope or a Zeiss Axiovert 200M microscope equipped with a humidified heated enclosure. Before imaging, culture medium was replaced with Leibovitz's L-15 medium (Gibco BRL) supplemented with 10% foetal bovine serum and penicillin/streptomycin. Cells were microinjected with cyclin B1-Venus cDNA (3 ng μl -1 ) during G2 phase of the cell cycle using a semiautomatic microinjector (Eppendorf) and assayed by time-lapse DIC and fluorescence microscopy 32 . EGFP was expressed under an IRES promoter to indentify injected cells. Images were captured at 3 or 5 min intervals and analysed by either SlideBook software (Intelligent Imaging Innovations) or Velocity LE Software (Improvision).
APC/C purification and ubiquitylation assays. HeLa cells were synchronised in G1/S phase using a single thymidine block for 24 h followed by a release either in DMA or taxol for 12 h. Cells were collected by mitotic shake off, washed in PBS, resuspended in extraction buffer (20 mM HEPES at pH 7.8, 175 mM NaCl, 2.5 mM MgCl 2 , 10% glycerol, 1 mM DTT, 1 mM PMSF, protease inhibitor cocktail -Roche, 2 μM ocadaic acid, 10 nM microcystin LR and phosphatase inhibitor cocktail II -Calbiochem). Cells were ruptured using nitrogen cavitation and cleared by centrifugation. APC/C was immunoprecipitated from 10 mg of extract using anti-APC3 antibodies (mAb AF3.1) immobilised to Dynabeads Protein G (Invitrogen). Single reactions were performed at 37 °C in 15 μl of QPIP buffer (50 mM PIPES at pH 7.5, 100 mM NaCl, 2 mM MgCl 2 , 10% glycerol, 1 mM DTT and 1 mM EGTA) containing 5 μl of APC3 beads, 300 nM E1, 2.6 μM E2, 150 μM ubiquitin or methyl ubiquitin (Calbiochem), 1 μM BSA, 100 nM CDC20, 100 nM radiolabelled substrate or 10 nM recombinant BUBR1, 2 mM ATP, 2.3 μM creatine kinase and 10 mM creatine phosphate. Reactions were stopped with SDS sample buffer and processed for SDS-PAGE. Dried gels were analysed by a phosphoimager (FLA-5000, FujiFilm) and quantifications were done using MacBas (FujiFilm). Autoradiographs of in vitro APC/C ubiquitylation assays used for the quantification of ubiquitin chains presented in Figure 4c . Recombinant UBCH10, UBCH5, UBE2S, and UBE2S C95S or the indicated combinations (at 1:1 molar ratio) were used for APC/C in vitro activity assays with 33 P-Cyclin B1 (aa1-86) as substrate. Reactions were performed for the indicated time before separation by SDS-PAGE and analysis using a phosphoimager. For the analysis shown in Figure 4c Cyclin B1-ubiquitin conjugates from gel regions 1-4, 5-9 or >9 generated during the first 25 minutes were quantified (to prevent the substrate becoming limiting). (b) The amount of unmodified Cyclin-B1 from (a) was measured to determine the rate of substrate ubiquitylation. Data are the average of 3 experiments and normalised to the total amount of Cyclin B1 at t=0. Error bars are SEM. Table S1 The ubiquitin-proteasome system siRNA library. A list of the 535 siRNA oligo pools targeting 520 components of the ubiquitin-proteasome system. This includes E1, E2 and E3 ubiquitin-conjugating enzymes and de-ubiquitylating enzymes.
Table S2
Mitotic index data and analysis from screen. The normalized mitotic index data from the DMSO and Monastrol treated plates for each of the 3 replicates. For each siRNA, the average and standard deviation of 3 replicates was determined and this was used to perform a Student's t-test compared to a non-targeting control siRNA (see methods). The ∆MI for each replicate pair (∆MI= MI Mona -MI DMSO ) was determined to identify genes that modify the response to mitotic arrest. The mitotic index values and standard deviations were used to calculate a standard score for each of the DMSO, Monastrol and ∆MI data sets.
